125 related articles for article (PubMed ID: 38554542)
21. Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC.
Zheng S; Li L; Chen M; Yang B; Chen J; Liu G; Shao Z; Wu J
Breast; 2022 Jun; 63():177-186. PubMed ID: 35429731
[TBL] [Abstract][Full Text] [Related]
22. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
23. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
Eur J Cancer; 2022 Nov; 176():30-40. PubMed ID: 36183652
[TBL] [Abstract][Full Text] [Related]
24. Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer.
Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
Eur J Cancer; 2023 Sep; 191():112956. PubMed ID: 37473465
[TBL] [Abstract][Full Text] [Related]
25. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER
Hayashi N; Yagata H; Tsugawa K; Kajiura Y; Yoshida A; Takei J; Yamauchi H; Nakamura S
Clin Breast Cancer; 2020 Dec; 20(6):462-468. PubMed ID: 33046356
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
27. Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Bergquist JR; Murphy BL; Storlie CB; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 Nov; 24(12):3510-3517. PubMed ID: 28828583
[TBL] [Abstract][Full Text] [Related]
28. Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.
Hamy AS; Lam GT; Laas E; Darrigues L; Balezeau T; Guerin J; Livartowski A; Sadacca B; Pierga JY; Vincent-Salomon A; Coussy F; Becette V; Bonsang-Kitzis H; Rouzier R; Feron JG; Benchimol G; Laé M; Reyal F
Breast Cancer Res Treat; 2018 Jun; 169(2):295-304. PubMed ID: 29374852
[TBL] [Abstract][Full Text] [Related]
29. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
30. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
31. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
32. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
33. The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer.
Teleki I; Krenacs T; Szasz MA; Kulka J; Wichmann B; Leo C; Papassotiropoulos B; Riemenschnitter C; Moch H; Varga Z
BMC Cancer; 2013 Feb; 13():50. PubMed ID: 23374644
[TBL] [Abstract][Full Text] [Related]
34. Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
Iwata H; Yamamoto Y; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Ohtani S; Kashiwaba M; Taira N; Toyama T; Fujisawa T; Masuda N; Shibahara Y; Sasano H; Yamaguchi T
Breast Cancer Res Treat; 2023 Jun; 199(2):231-241. PubMed ID: 36947277
[TBL] [Abstract][Full Text] [Related]
35. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
36. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers.
Crosbie A; Le TK; Zhang Y; Das R; Ades F; Davis C; Gogate A
Future Oncol; 2023 Jan; 19(3):229-244. PubMed ID: 36974619
[TBL] [Abstract][Full Text] [Related]
38. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
39. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.
Mittendorf EA; Jeruss JS; Tucker SL; Kolli A; Newman LA; Gonzalez-Angulo AM; Buchholz TA; Sahin AA; Cormier JN; Buzdar AU; Hortobagyi GN; Hunt KK
J Clin Oncol; 2011 May; 29(15):1956-62. PubMed ID: 21482989
[TBL] [Abstract][Full Text] [Related]
40. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
Breast Cancer Res Treat; 2016 Dec; 160(3):475-489. PubMed ID: 27730423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
